Barriers to using warfarin in non-valvular atrial fibrillation

doi:10.1136/bmj.332.7536.303-b

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

This article has a correction

Please see: Barriers to using warfarin in non-valvular atrial fibrillation

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Melina Gattellari, research fellow (Melina.Gattellari@sswahs.nsw.gov.au),
Nicholas A Zwar, director,
John M Worthington, senior staff specialist in neurology,
Sandy Middleton, professor of nursing

General Practice Unit, School of Public Health and Community Medicine, University of New South Wales, Kensington, NSW 2052, Australia
General Practice Unit, School of Public Health and Community Medicine, University of New South Wales, Kensington, NSW 2052, Australia
Liverpool Health Service. Locked Bag 7017, Liverpool, NSW 1871
School of Nursing (NSW), ACU National, PO Box 968, North Sydney, NSW 2059

EDITOR—Anticoagulation is underused in the treatment of non-valvular atrial fibrillation. Choudhry et al show that adverse outcomes from anticoagulation have greater influence on its management than occurrences of avoidable ischaemic stroke.1 They speculate that this result arises from undue fear or concern about adverse consequences of anticoagulation.

We are conducting a representative national survey of 1000 Australian general practitioners, addressing how fear of anticoagulation affects management of non-valvular atrial fibrillation. Our preliminary findings indicate that aversion to the risk of …